Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

Colorectal Neoplasms, Neoplasm, Residual

Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Pathologic Complete Response, Rectal Neoplasms

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Esophageal Squamous Cell Carcinoma

Lymphoma, Follicular

Carcinoma, Hepatocellular

Carcinoma, Non-Small-Cell Lung

Squamous Cell Carcinoma of External Auditory Canal

Carcinoma, Hepatocellular

Pseudomyxoma Peritonei

Locally Advanced Rectal Carcinoma

Esophageal Squamous Cell Carcinoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Squamous Cell Carcinoma of Head and Neck

Colorectal Neoplasms

Muscle Invasive Bladder Cancer (MIBC)

Adenocarcinoma Of Esophagus, Stomach Neoplasms

Colorectal Neoplasms

Lung Neoplasms

Hodgkin Disease, Lymphoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Renal Pelvic Carcinoma

Colorectal Neoplasms

Small Cell Lung Carcinoma

Biliary Tract Neoplasms

Rectal Neoplasms

Head and Neck Neoplasms

Perioperative Immunotherapy

Carcinoma, Non-Small-Cell Lung

Rectal Neoplasms

Advanced Solid Tumor

Carcinoma, Non-Small-Cell Lung

Carcinoma, Hepatocellular

Squamous Cell Carcinoma of Head and Neck

Colorectal Neoplasms

Esophageal Squamous Cell Carcinoma

Carcinoma, Non-Small-Cell Lung

Stomach Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Colonic Neoplasms, Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Sarcoma

Carcinoma, Hepatocellular, Recurrence

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis

Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma

SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC

Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal

Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

Pseudovax

A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer

TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy

Endosurgery-02

Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer

A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.

FUTURE

HARBOR

NeoTISLEGA

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer

FIL_Tisle-HL

Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma

Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer

Tislelizumab in People With Colorectal Cancer

Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC

GENTIS

Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study

Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors

Perioperative Immunotherapy for Resectable Limited-Stage SCLC

Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer

TOTAL

A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

LEAF-01

A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma

Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients

Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma

A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore

SACTION2401

Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer

UMBRELLA

Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC